when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

CD19 · news · pharmadog

← back to CD19

News · CD19

34 stories

19hWeighing the risks of CAR T in autoimmune disease as Kyverna nears marketbiospace

19hWeighing the risks of CAR T in autoimmune disease as Kyverna nears marketbiospace

3dFoghorn cuts 40% of workforcebiospace

3dNovartis wagers almost $8B on a Chinese biotech’s RNA drugsbiopharma dive

3dNovartis takes rights to Abogen's mRNA T cell engager for $575M upfrontendpoints

3dNovartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerfiercebiotech

4dChutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOfiercebiotech

7dai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’fiercebiotech

10dAdicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approachesfiercebiotech

11dKyverna steps closer to FDA-first CAR T for an autoimmune condition with durability databiospace

12dKyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snagsfiercebiotech

20dGSK bags Chimagen’s trispecific T cell engager in deal worth up to $750Mbiospace

21dUnlocking cell surface protein research with site-specific labelingbiospace

Sep 3, 26The hidden scale-out problem behind CAR-T’s growthbiopharma dive

Sep 3, 26AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialfiercebiotech

Sep 1, 26Roche finds another oncology gem in Asia with $1.5B B cell disease partnershipbiospace

Sep 1, 26Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety eventsbiospace

Sep 1, 26Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyfiercebiotech

Sep 1, 26Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also pausedendpoints

Aug 31, 26UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studiesfiercebiotech

Aug 28, 26CAR T for autoimmune disease benefits from oncology’s lessons—and will deliver its ownbiospace

Aug 27, 26CAR Ts will only treat autoimmune diseases if we can scale deliverybiospace

Aug 26, 26BMS ends Cellares pact over cell therapy production problems, triggering layoffsbiospace

Aug 14, 26After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?fiercebiotech

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 11, 26Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsfiercebiotech

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 29, 26Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapybiospace

Jul 27, 26Legend Biotech CEO abruptly steps down without permanent replacementfiercebiotech

Jul 27, 26Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace

← prevpage 1 of 2next →